Genedata Screener Strengthens Collaborative Research at Axxam
| Platform enables consistent production of high-quality data and increases the pace of innovation at CROs and PROs |
|
Basel, Switzerland – Genedata, a leading provider of advanced software solutions for R&D, today announced that Axxam has extended its licensing of Genedata Screener® as its collaborative research platform for data analysis of high-throughput screening, compound profiling, and safety screening campaigns. As an innovative Partner Research Organization (i-PRO), Axxam provides integrated discovery services for the whole life sciences industry. The Genedata Screener platform is used to streamline and standardize Axxam screening workflows, and Axxam has successfully extended its use of Genedata Screener as a collaboration platform with its many biopharma clients and partners.
Genedata Screener: Competitive Edge for CROs and PROs
“Since 2008, we have been using Genedata Screener for high throughput screening programs,” says Dr. Stefan Lohmer, CEO of Axxam. “The platform is integral to all our screening service offerings and provides everything our customers are looking for in terms of data comparability, traceability, and quality of results.”
Web-based and cloud-ready, Genedata Screener gives Axxam a collaborative platform that simplifies data- and result-sharing. It supports different collaboration models between i-PROs and pharmaceutical companies, such as multi-tiered and peer-to-peer, which empowers new approaches to drug discovery.
“The cost savings, productivity gains, and increased opportunities for innovative R&D are driving the increased adoption of Genedata Screener by the world’s leading PROs,” noted Dr. Othmar Pfannes. “We are committed to supporting PROs and their clients in their collaborations to make biopharmaceutical R&D processes more efficient.”
About Genedata |

